Current oncology (Toronto, Ont.) · 2025
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dankner Matthew, Dubé Laurie-Rose, Sorin Mark, Stein Andrew J B, Nowakowski Alexander, Park Changsu Lawrence, Magrill Jamie, Lazaratos Anna-Maria, Romero Joan Miguel, Batist Gerald, Kavan Petr, Rose April A N, Ma Kim
Аннотация
BACKGROUND: BRAF mutations are found in 10% of colon cancers (CCs) and are associated with poor prognosis in metastatic disease. BRAF V600E predicts sensitivity to cetuximab + encorafenib in the metastatic setting. With new trials testing encorafenib-containing regimens for early-stage CC, we sought to characterize the clinical outcomes of early-stage BRAF V600E CC.
METHODS: We performed a systematic review and meta-analysis. Key inclusion criteria were a diagnosis of stage 2/3 BRAF V600E CC. Co-primary endpoints were overall survival (OS) and recurrence/disease-free survival (DFS). Meta-analysis was performed with a random-effects model incorporating sample size, hazard ratio (HR), and 95% confidence intervals (CIs).
RESULTS: A total of 206 studies underwent full-text review. Of these, six randomized controlled trials were included, comprising 6836 and 843 patients with wild-type (WT) and BRAF V600E, respectively. BRAF V600E was associated with inferior OS (HR 1.49, CI 1.21-1.75) and DFS (HR 1.17, CI 1.03-1.33). This finding remains in patients with microsatellite instability-low/stable or proficient mismatch repair (OS: HR 1.66, CI 1.36-2.02, DFS: HR 1.45, CI 1.22-1.72).
CONCLUSIONS: BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.
METHODS: We performed a systematic review and meta-analysis. Key inclusion criteria were a diagnosis of stage 2/3 BRAF V600E CC. Co-primary endpoints were overall survival (OS) and recurrence/disease-free survival (DFS). Meta-analysis was performed with a random-effects model incorporating sample size, hazard ratio (HR), and 95% confidence intervals (CIs).
RESULTS: A total of 206 studies underwent full-text review. Of these, six randomized controlled trials were included, comprising 6836 and 843 patients with wild-type (WT) and BRAF V600E, respectively. BRAF V600E was associated with inferior OS (HR 1.49, CI 1.21-1.75) and DFS (HR 1.17, CI 1.03-1.33). This finding remains in patients with microsatellite instability-low/stable or proficient mismatch repair (OS: HR 1.66, CI 1.36-2.02, DFS: HR 1.45, CI 1.22-1.72).
CONCLUSIONS: BRAF V600E is associated with inferior prognoses compared to BRAF WT in early-stage CC. This finding will help optimize trial design for this population.